November 14, 2024 at 02:49PM FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

FDA Approves Kebilidi, an adeno-associated virus vector-based gene therapy indicated for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency.

via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/wjNzJVu